Barriers to guideline-compliant psoriasis care: Analyses and concepts

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 4, 2016, Pages 569-575

  Eissing, L ^a   Radtke, M A ^a   Zander, N ^a   Augustin, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMORBIDITY; EMPOWERMENT; HEALTH CARE COST; HEALTH CARE DISPARITY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PSORIASIS; PSYCHOLOGICAL ASPECT; REIMBURSEMENT; REVIEW; SUPPORT GROUP; PATHOPHYSIOLOGY; PROTOCOL COMPLIANCE; QUALITY OF LIFE;

GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSORIASIS; QUALITY OF LIFE;

EID: 84962128698     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13452     Document Type: Review

References (65)

1. Parisi R, Symmons DP, Griffiths CE, et al,. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
2. Schäfer I, Rustenbach SJ, Radtke M, et al,. Epidemiologie der Psoriasis in Deutschland-Auswertung von Sekundärdaten einer gesetzlichen Krankenversicherung. Gesundheitswesen 2011; 73: 308-313.
3. Augustin M, Glaeske G, Radtke MA, et al,. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-636.
4. Berger K, Ehlken B, Kugland B, et al,. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005; 3: 511-518.
5. Sohn S, Schoeffski O, Prinz J, et al,. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006; 212: 137-144.
6. Augustin M, Radtke MA,. Health economic issues in psoriasis. Expert Rev Dermatol 2008; 3: 19-23.
7. Zachariae R, Zachariae H, Blomqvist K, et al,. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002; 146: 1006-1016.
8. Böhm D, Stock Gissendanner S, Bangemann K, et al,. Perceived relationships between severity of psoriasis symptoms, gender, sigmatization and quality of life. J Eur Acad Dermatol Venereol 2013; 27: 220-226.
9. Sampogna F, Tabolli S, Abenti D,. IDI, Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) investigators. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol 2012; 92: 299-303.
10. Misery L,. Depression and psoriasis. Ann Dermatol Venreol 2012; 139: 53-57.
11. Hrehorów E, Salomon J, Matusiak L, et al,. Patients with psoriasis feel stigmatized. Acta Dermato-Venereologica 2012; 92: 67-72.
12. Blome C, Simianer S, Purwins S, et al,. Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 2010; 221: 154-159.
13. Kimball AB, Gieler U, Linder D, et al,. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989-1004.
14. Augustin M,. Cumulative life course impairment: identifying patients at risk. Curr Probl Dermatol 2013; 44: 74-81.
15. Reich K, Krüger K, Mössner R, et al,. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040-1047.
16. Radtke MA, Reich K, Blome C, et al,. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009; 23: 683-691.
17. Augustin M, Reich K, Glaeske G, et al,. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151.
18. Reich K,. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol 2012; 26 (Suppl 2): 3-11.
19. Boehncke WH, Boehncke S,. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanism, therapeutic implications, and perspectives. Curr Rheumatol Rep 2012; 14: 343-348.
20. Garcia-Doval I, Rustenbach SJ, Stern R, et al,. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Br J Dermatol 2013; 169: 710-714.
21. Radtke MA, Augustin J, Blome C, et al,. How do regional factors influence psoriasis patient care in Germany? J Dtsch Dermatol Ges 2010; 8: 516-524.
22. Augustin M, Reich K, Reich C, et al,. Quality of psoriasis care in Germany-results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 2007; 6: 640-645.
23. Augustin M, Schäfer I, Reich K, et al,. Systemic treatment with corticosteroids in psoriasis-health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges 2011; 9: 833-838.
24. Nast A, Boehncke WH, Mrowietz U, et al,. German S3-guidelines on the treatment of psoriasis vulgaris (short version). J Dtsch Dermatol Ges 2012; 304: 87-113.
25. Augustin M, Krüger K, Radtke MA, et al,. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372.
26. Radtke MA, Reich K, Blome C, et al,. Evaluation of quality of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 2009; 219: 54-58.
27. Fifty-eighth World Health Assembly (2005). Sustainable health financing, universal coverage and social health insurance [WWW document]. URL http://apps.who.int/iris/bitstream/10665/20383/1/WHA58-33-en.pdf?ua&=1 [last accessed: 10 April 2015].
28. Augustin M, Holland B, Dartsch D, et al,. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011; 222: 363-374.
29. Richards HL, Fortune DG, Griffiths CEM,. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 370-379.
30. Renzi C, Picardi A, Abeni D, et al,. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337-342.
31. Young SD, Oppenheimer DM,. Different methods of presenting risk information and their influence on medication compliance intentions: results of three studies. Clin Ther 2006; 28: 129-139.
32. Wolf MS, Davis TC, Shrank W, et al,. To err is human: patient misinterpretations of prescription drug label instructions. Patient Educ Couns 2007; 67: 293-300.
33. Pouplard C, Gourraud P, Meyer N, et al,. Are we giving patients enough information on how to use topical treatments? Analysis of 767 prescriptions in psoriasis. Br J Dermatol 2011; 165: 1332-1336.
34. Schmieder A, Schaarschmidt M, Umar N, et al,. Comorbidities significantly impact patients' preferences for psoriasis treatments. J Am Acad Dermatol 2012; 67: 363-372.
35. Navarini AA, Laffitte E, Conrad C, et al,. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010; 140: 85-91.
36. Gunnarsson C, Chen J, Rizzo JA, et al,. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatolog Treat 2012; 23: 240-254.
37. Bhutani T, Wong JW, Bebo BF, et al,. Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol 2013; 149: 717-721.
38. Briesacher BA, Gurwitz JH, Soumerai SB,. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med 2007; 22: 864-871.
39. Zimmerman GM, Savage LM, Chandler DC, Maccarone Buonfigli M,. Psoriatic arthritis and psoriasis: role of patient advocacy organisations in the twenty-first century. Ann Rheum Dis 2005; 64 (Suppl II): ii93-ii100.
40. Nijsten T, Rolstad T, Feldman SR, et al,. Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol 2005; 141: 19-26.
41. Nijsten T, Bergstresser PR,. Patient advocacy groups: let's stick together. J Invest Dermatol 2010; 130: 1757-1759.
42. Cabana MD, Rand CS, Powe NR, et al,. Why don't physicians follow clinical practice guidelines? A framework for improvement JAMA 1999; 282: 1458-1465.
43. Cochrane LJ, Olson CA, Murray S, et al,. Gaps between knowing and doing: understanding and assessing the barriers to optimal health care. J Contin Educ Health Prof 2007; 27: 94-102.
44. Wan J, Abuabara K, Troxel AB, et al,. Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. J Am Acad Dermatol 2012; 66: 376-386.
45. Abuabara K, Wan J, Troxel AB, et al,. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68: 262-269.
46. Nast A, Mrowietz U, Kragballe K, et al,. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis-a multinational cross-sectional study. Arch Dermatol Res 2013; 305: 899-907.
47. Augustin M, Radtke MA,. Health economic issues in psoriasis. Expert Rev Dermatol 2008; 3 (Suppl 4): S19-S23.
48. Bagel J,. Evaluating the current state of psoriasis care. Pract Dermatol 2011; 2011: 58-62.
49. Augustin M, Glaeske G, Schäfer I, et al,. Processes of psoriasis health care in Germany-long-term analysis of data from the statutory health insurances. J Dtsch Dermatol Ges 2012; 10: 648-655.
50. Samarasekera EJ, Smith CH,. Psoriasis: guidance on assessment and referral. Clin Med 2014; 14: 178-182.
51. Daudén E, Castañeda S, Suárez C, et al,. Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis. J Eur Acad Dermatol Venereol 2013; 27: 1387-1404.
52. Luelmo J, Gratacós J, Moreno Martínez-Losa M, et al,. Multidisciplinary psoriasis and psoriatic arthritis unit: report of 4 years' experience. Actas Dermosifiliogr 2014; 105: 371-377.
53. Nell VPK, Machold KP, Eberl G, et al,. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 906-914.
54. Coates LC, Navarro-Coy N, Brown SR, et al,. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Dis 2013; 14: 101.
55. Nast A, Mrowietz U, Kragballe K, et al,. National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. Arch Dermatol Res 2013; 305: 637-643.
56. Wakkee M, Lugtenberg M, Spuls PI, et al,. Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists. Br J Dermatol 2008; 159: 426-432.
57. Taba P, Rosenthal M, Habicht J, et al,. Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res 2012; 12: 455.
58. Reich K, Mrowietz U,. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007; 5: 566-574.
59. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
60. Radtke MA, Reich K, Spehr C, Augustin M,. Treatment goals in psoriasis routine care. Arch Dermatol Res 2015; 307: 445-449.
61. Zweegers J, van den Reek JM, van de Kerkhof PCM, et al,. Comparing treatment goals for psoriasis to treatment decisions in daily practice. Results from a prospective cohort of psoriasis patients treated with biologics: Bio-Capture. Br J Dermatol 2014; 171: 1091-1098.
62. Baker C, Mack A, Cooper A, et al,. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol 2013; 54: 148-154.
63. Brezinski EA, Armstrong AW,. Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. Semin Cutan Med Surg 2014; 33: 91-97.
64. Ashcroft DM, Wan Po AL, Williams HC, et al,. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-191.
65. World Health Assembly. Psoriasis [WWW document] 2014. URL http://apps.who.int/gb/ebwha/pdf-files/WHA67/A67-R9-en.pdf [last accessed: 10 April 2015].